Randomised controlled trial

Anthracyclines and Biomarkers of Myocardial Injury

JACC CardioOncolPublished

  • Randomised controlled trial
  • single-blind
  • sham-controlled
  • prematurely halted

Authors' conclusion

TnT and cMyC significantly increased during anthracycline chemotherapy with 81% having a TnT ≥14 ng/L at cycle 6. RIC did not affect the rise in biomarkers, but there was a small increase in early cancer deaths, possibly related to the greater proportion of patients with metastatic disease randomized to the RIC group (54%vs 37%).

Study context

Population
Patients receiving anthracycline chemotherapyprematurely halted
Participants
55 patients
Comparison
Remote ischemic conditioning (RIC) vs sham at each chemotherapy cycle
  • RICn = 28
  • Shamn = 27reference
Primary endpoint
Troponin T (TnT) during chemotherapy
Follow-up
Up to 1 year

Primary result

As reported in the abstract

TnT (mixed-effects regression, repeated measures)

Mean difference

3.15 ng/L

95% CI −0.04 to 6.33

P = 0.053

RIC vs Sham
mean difference 3.15 ng/L (95% CI −0.04 to 6.33); P = 0.053

Secondary outcomes

Outcomemean difference (ng/L) (95% CI)P value
cMyC (mixed-effects regression, repeated measures)4.17 (−0.12 to 8.45)P = 0.056

events

OutcomeRICShamHR (95% CI)P value
MACE and cancer deaths · up to 1 year · more events with RIC1130.25 (0.07–0.90)P = 0.034
Cancer deaths · up to 1 year · more cancer deaths with RIC810.21 (0.04–0.95)P = 0.043
  • Cancer deaths: metastatic disease 54% RIC vs 37% sham

Biomarkers, baseline to cycle 6, all patients

Median troponin T (TnT) 6 [IQR: 4-9] ng/L to 33 [IQR: 16-36)] ng/L
P ≤ 0.001
Median cMyC 3 (IQR: 2-5) ng/L to 47 (IQR: 18-49) ng/L
P ≤ 0.001

Original publication

Anthracyclines and Biomarkers of Myocardial Injury. JACC CardioOncol. Published 2 May 2023. doi:10.1016/j.jaccao.2023.03.008

Summarised from the published abstract; every number is checked against it